← Back to all trials
Recruiting
NCT07929519
Clinical Characteristics, Treatment, Diagnostic Findings, and Outcomes of Tuberculous Meningitis in Indonesia, 2022-2025
Conditions: Tuberculous Meningitis
Sex: All
Healthy volunteers: No
Enrollment: 300
Sponsor: Ina-Respond
Location: Site 520: RSUP Prof Dr I.G.N.G. Ngoerah Denpasar Bali
Summary
TBM Study is a multicenter, observational, retrospective cohort study of Tuberculous Meningitis (TBM) patients who underwent treatment at the hospital during the 2022-2025 period. The goal of this study is to learn about the clinical characteristics, diagnostic findings, drug resistance profiles, treatment regimens, complications, and treatment outcomes of patients diagnosed with TBM who were admitted to the study hospitals between 2022 and 2025. This study uses retrospective data obtained from electronic medical records (EMR).
Eligibility Criteria
Inclusion Criteria:
* Admited to the participating hospital sites between January 1, 2022, and December 31, 2025
* Have a discharge diagnosis of TBM (ICD-10 code A17.0) or documented TBM diagnosis in the hospital EMR system.
* Have accessible data available in the EMR.
Exclusion Criteria:
None
Source: ClinicalTrials.gov (NCT07929519). StuddyBuddy aggregates publicly available trial information.
